Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma, Ewing × alovudine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 2 Sarcoma, Ewing 1 Prostatic Neoplasms 1 Neoplasms 1 Lymphoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 6 Irinotecan 6 Vincristine 3 PM 01183 3 Nivolumab 3 X-Rays 2 Cyclophosphamide 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 seclidemstat 1 rubitecan 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 entrectinib 1 efineptakin alfa 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 anlotinib 1 alovudine 1 abemaciclib 1 Zoledronic Acid 1 Trabectedin 1 Topotecan 1 TQ-B3525 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04067115 2025-12-17

U01CA236220

Sarcoma Alliance for Research through Collaboration

Phase 1/2 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡